Both GR metrics analyses and endpoint cell viability assays showed that gedatolisib generally exerted greater anti‐proliferative and cytotoxic effects compared to single‐node PAM inhibitors (alpelisib, capivasertib, everolimus) or to a less uniformly potent pan‐PI3K/mTOR inhibitor (samotolisib), regardless of the PTEN status or androgen sensitivity of the PC cells. The gene discussed is PIK3CA; the disease is pachyonychia congenita.